Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) setting. Patients & methods: We studied retrospecti...

Description complète

Détails bibliographiques

Auteurs principaux:	Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Format:	Artigo
Langue:	Inglês
Publié:	Becaris Publishing Limited 2023-12-01
Collection:	Journal of Comparative Effectiveness Research
Sujets:	acute lymphoblastic leukemia costs health care resource utilization medications relapse/refractory
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!